This topic contains a solution. Click here to go to the answer

Author Question: Assume that an oligopolist has a kinked demand curve. Suppose that the marginal cost curve passes ... (Read 70 times)

jho37

  • Hero Member
  • *****
  • Posts: 531
Assume that an oligopolist has a kinked demand curve. Suppose that the marginal cost curve passes through the gap in the marginal revenue curve. This means price and output will be shown by a point:
 a. above the curve.
  b. below the curve.
  c. at the kink
  d. on the upper part of the curve.
  e. on the lower part of the curve.

Question 2

In the short run, a firm will eventually experience rising per-unit costs because of:
 a. economies of scale.
  b. diseconomies of scale.
  c. the law of supply.
  d. the law of diminishing returns.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

IRincones

  • Sr. Member
  • ****
  • Posts: 321
Answer to Question 1

c

Answer to Question 2

d




jho37

  • Member
  • Posts: 531
Reply 2 on: Jun 30, 2018
Thanks for the timely response, appreciate it


lcapri7

  • Member
  • Posts: 350
Reply 3 on: Yesterday
Great answer, keep it coming :)

 

Did you know?

Certain rare plants containing cyanide include apricot pits and a type of potato called cassava. Fortunately, only chronic or massive ingestion of any of these plants can lead to serious poisoning.

Did you know?

The Babylonians wrote numbers in a system that used 60 as the base value rather than the number 10. They did not have a symbol for "zero."

Did you know?

This year, an estimated 1.4 million Americans will have a new or recurrent heart attack.

Did you know?

Children of people with alcoholism are more inclined to drink alcohol or use hard drugs. In fact, they are 400 times more likely to use hard drugs than those who do not have a family history of alcohol addiction.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library